{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T19:56:40Z","timestamp":1760385400074},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,11,26]],"date-time":"2014-11-26T00:00:00Z","timestamp":1416960000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00134-014-3572-5","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T16:05:12Z","timestamp":1417536312000},"page":"157-159","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Continuous administration of linezolid in pneumonia: what is the level of proof?"],"prefix":"10.1007","volume":"41","author":[{"given":"Olivier","family":"Mimoz","sequence":"first","affiliation":[]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9-Artur","family":"Paiva","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2014,11,26]]},"reference":[{"issue":"Suppl 4","key":"3572_CR1","first-page":"iv7","volume":"66","author":"MS Dryden","year":"2011","unstructured":"Dryden MS (2011) Linezolid pharmacokinetics and pharmacodynamics in clinical treatment. J Antimicrob Chemother 66(Suppl 4):iv7\u2013iv15","journal-title":"J Antimicrob Chemother"},{"key":"3572_CR2","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(14)70036-2","volume":"14","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW, Hope WW, Farkas A, Neely MN, Schentag JJ, Drusano G, Frey OR, Theuretzbacher U, Kuti JL, International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases (2014) Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis 14:498\u2013509","journal-title":"Lancet Infect Dis"},{"key":"3572_CR3","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1097\/01.CCM.0000207339.11477.62","volume":"34","author":"C Pangault","year":"2006","unstructured":"Pangault C, Le Tulzo Y, Tattevin P, Guilloux V, Bescher N, Dr\u00e9nou B (2006) Down-modulation of granulocyte macrophage-colony stimulating factor receptor on monocytes during human septic shock. Crit Care Med 34:1193\u20131201","journal-title":"Crit Care Med"},{"key":"3572_CR4","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1128\/AAC.45.8.2304-2308.2001","volume":"45","author":"CF Dailey","year":"2001","unstructured":"Dailey CF, Dileto-Fang CL, Buchanan LV, Oramas-Shirey MP, Batts DH, Ford CW, Gibson JK (2001) Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 45:2304\u20132308","journal-title":"Antimicrob Agents Chemother"},{"key":"3572_CR5","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/cc13984","volume":"18","author":"M Zoller","year":"2014","unstructured":"Zoller M, Maier B, Hornuss C, Neugebauer C, D\u00f6bbeler G, Nagel D, Holdt LM, Bruegel M, Weig T, Grabein B, Frey L, Teupser D, Vogeser M, Zander J (2014) Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care 18:R148","journal-title":"Crit Care"},{"key":"3572_CR6","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1128\/AAC.01694-12","volume":"57","author":"L Morata","year":"2013","unstructured":"Morata L, Cuesta M, Rojas JF, Rodriguez S, Brunet M, Casals G, Cobos N, Hernandez C, Martinez JA, Mensa J, Soriano A (2013) Risk factors for a low linezolid trough plasma concentration in acute infections. Antimicrob Agents Chemother 57:1913\u20131917","journal-title":"Antimicrob Agents Chemother"},{"key":"3572_CR7","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2007.09.009","volume":"31","author":"C Adembri","year":"2008","unstructured":"Adembri C, Fallani S, Cassetta MI, Arrigucci S, Ottaviano A, Pecile P, Mazzei T, De Gaudio R, Novelli A (2008) Linezolid pharmacokinetic\/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 31:122\u2013129","journal-title":"Int J Antimicrob Agents"},{"key":"3572_CR8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00228-009-0766-9","volume":"66","author":"S Swoboda","year":"2010","unstructured":"Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA (2010) Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 66:291\u2013298","journal-title":"Eur J Clin Pharmacol"},{"key":"3572_CR9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.ijantimicag.2013.02.020","volume":"41","author":"D Cattaneo","year":"2013","unstructured":"Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S, Fucile S, Gulisano C, Rizzardini G, Clementi E (2013) Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with Gram-positive infections. Int J Antimicrob Agents 41:586\u2013589","journal-title":"Int J Antimicrob Agents"},{"key":"3572_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/01.CCM.0000297885.60037.6E","volume":"36","author":"ME Akinnusi","year":"2008","unstructured":"Akinnusi ME, Pineda LA, El Solh AA (2008) Effect of obesity on intensive care morbidity and mortality: a meta-analysis. Crit Care Med 36:151\u2013158","journal-title":"Crit Care Med"},{"key":"3572_CR11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1378\/chest.12-2310","volume":"144","author":"G Kumar","year":"2013","unstructured":"Kumar G, Majumdar T, Jacobs ER, Danesh V, Dagar G, Deshmukh A, Taneja A, Nanchal R (2013) Outcomes of morbidly obese patients receiving invasive mechanical ventilation: a nationwide analysis. Chest 144:48\u201354","journal-title":"Chest"},{"key":"3572_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.soard.2012.01.025","volume":"9","author":"H Masoomi","year":"2013","unstructured":"Masoomi H, Reavis KM, Smith BR, Kim H, Stamos MJ, Nguyen NT (2013) Risk factors for acute respiratory failure in bariatric surgery: data from the Nationwide Inpatient Sample, 2006\u20132008. Surg Obes Relat Dis 9:277\u2013281","journal-title":"Surg Obes Relat Dis"},{"key":"3572_CR13","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.soard.2011.04.227","volume":"8","author":"PK Gupta","year":"2012","unstructured":"Gupta PK, Gupta H, Kaushik M, Fang X, Miller WJ, Morrow LE, Armour-Forse R (2012) Predictors of pulmonary complications after bariatric surgery. Surg Obes Relat Dis 8:574\u2013581","journal-title":"Surg Obes Relat Dis"},{"key":"3572_CR14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1128\/AAC.01083-12","volume":"57","author":"M Hites","year":"2013","unstructured":"Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F (2013) Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 57:708\u2013715","journal-title":"Antimicrob Agents Chemother"},{"key":"3572_CR15","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkt444","volume":"69","author":"MJ Brill","year":"2014","unstructured":"Brill MJ, Houwink AP, Schmidt S, Van Dongen EP, Hazebroek EJ, van Ramshorst B, Deneer VH, Mouton JW, Knibbe CA (2014) Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. J Antimicrob Chemother 69:715\u2013723","journal-title":"J Antimicrob Chemother"},{"key":"3572_CR16","author":"G Pascale De","year":"2014","unstructured":"De Pascale G, Fortuna S, Tumbarello M, Cutuli SL, Vallecoccia M, Spanu T, Bello G, Montini L, Pennisi MA, Navarra P, Antonelli M (2014) Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration. Intensive Care Med. doi: 10.1007\/s00134-014-3550-y","journal-title":"Intensive Care Med"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-014-3572-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00134-014-3572-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-014-3572-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T13:00:14Z","timestamp":1558616414000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00134-014-3572-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["3572"],"URL":"https:\/\/doi.org\/10.1007\/s00134-014-3572-5","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,26]]}}}